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Abstract: Parkinson’s disease (PDI is a neurodegenerative disorder of unknown etiology. Both genetic and environmental 
factors are thought to be implicated to some extent. The ACE gene insertion/deletion (I/D) polymorphism has been asso-
ciated with common neurodegenerative disorders that share similar clinical and neuropathological features with PD (Alz-
heimer’s disease). In this study we set out to examine the role of the ACE gene insertion/deletion (I/D) polymorphism in 
Parkinson’s disease (PD). 
We conducted a case-control association study among 77 PD patients and 50 non-PD controls from Greece.  
The genotype frequencies for II, ID, and DD were 39, 48, and 13%, respectively, in the PD group and 32, 50, and 18% in 
the control group. Although the DD frequency was higher in the case group statistical significance was not reached.  
We conclude that although disease modifying effects cannot be excluded, the ACE insertion/deletion polymorphism is un-
likely to be an important determinant of susceptibility to PD in this population.  
Keywords: Angiotensin Converting Enzyme, ACE, Polymorphism, Insertion-deletion, Parkinson’s disease, Association study. 
1. INTRODUCTION 
  Parkinson’s disease (PD) is one of the most common 
neurodegenerative disorders characterized by selective neu-
rodegeneration, leading to extrapyramidal, hypokinetic mo-
tor dysfunction (tremor, rigidity, bradykinesia). However, 
parkinsonian disorders may present with the additional 
atypical features of neuropsychiatric (dementia, depression, 
psychosis) and autonomic involvement. Pathogenic muta-
tions in at least seven different genes are implicated in park-
insonism highlighting the importance of genetic factors and 
heterogeneous nature of the syndrome [1]. This clinical het-
erogeneity is also noted with similar characteristics in the 
presentation of other neurodegenerative disorders like Alz-
heimer’s disease (AD), which share clinical and pathological 
characteristics with PD [2].  
  One candidate gene investigated for its relevance in neu-
rodegeneration in both AD [3, 4] and PD [5, 6] is the angio-
tensin-converting enzyme (ACE). ACE increases blood pres-
sure through conversion of angiotensin I (inactive) to the 
potent vasoconstrictor angiotensin II [7]. Moreover, ACE is  
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a major pathway for the degradation of bradykinin [8], a 
peptide of the kinin family involved in the regulation of vas-
cular tone that also participates in the peripheral inflamma-
tory response [9]. Apart from angiotensin II and bradykinin, 
endogenously occurring neuro-peptides, like substance P and 
opioid peptides have been identified as ACE substrates. An 
insertion/deletion (I/D) polymorphism of the ACE gene [10] 
accounting for half the variance in serum ACE levels has 
been described. We set out to study this ACE gene polymor-
phism, in a well characterized cohort of PD patients and 
aged control subjects. 
2. MATERIALS AND METHODS 
2.1. Study Population 
  The study population consisted of 77 patients with idio-
pathic PD and 50 controls. PD patients were consecutively 
recruited in the Department of Neurology of the Regional 
University Hospital of Patras, Greece (a tertiary referral cen-
ter) over a period of 2 years. The controls were randomly 
selected from patients seen in the Regional University Hos-
pital Evagelismos, Athens, Greece and were identified as 
healthy (no identifiable medical condition including neuro-
logical disorder) by their treating physicians. All PD patients 
and controls were Caucasians, genetically unrelated and of 
Greek origin. Informed consent was obtained from all the 
subjects. Diagnosis of PD was made according to the UK PD ACE Insertion/Deletion Polymorphism and Parkinson’s Disease  The Open Neurology Journal, 2008, Volume 2    67 
Society Brain Bank diagnostic criteria [11]. Thus, only pa-
tients who had bradykinesia and at least two of rigidity, rest 
tremor and postural instability were included. All patients 
were investigated with either brain CT or MRI. Cases con-
sidered as atypical parkinsonism, vascular parkinsonism, or 
any PD plus syndrome, were excluded from the study.  
  During a semi-structured interview demographic data, 
complete past medical history, age of PD onset, modality of 
presentation, duration of PD, and dosage of levodopa therapy 
were collected. The Unified Parkinson's Disease Rating 
Scale (UPDRS) [12] was completed during clinical examina-
tion and was used for evaluation of disease severity. This 
includes UPDRS I (mentation, behaviour and mood), 
UPDRS II (activities of daily living), UPDRS III (motor ex-
amination), UPDRS IV (complications of therapy), Hoehn & 
Yahr scale [13] (measures the severity of the disease and is 
based on lateralization of the symptoms and balance evalua-
tion) and Schwab & England scale [14] (also measures ac-
tivities of daily living).  
2.2. Laboratory Technique 
  Genomic DNA was isolated from whole blood using the 
NucleoSpin Blood L kit (Mecherey – Nagel) following the 
protocol recommended by the manufacturer. To determine 
the 287-bp insertion/deletion polymorphism in intron 16 of 
the ACE gene, a conventional PCR [10] was performed us-
ing 500 ng genomic DNA as template with a flanking primer 
pair 5’ CTG GAG ACC ACT CCC ATC CTT TCT 3’ and 5’ 
GAT GTG GCC ATC ACA TTC GTC AGA T-3’ in a solu-
tion of 25 μl containing 20 pmol of each primer, 0,5mM 
dNTP, 2mM Mg, 10mM Tris-HCl (pH 8.8), 50mM  KCl, 
0.08% Nonidet P40 and 1unit of Taq DNA Polymerase, 
(Fermentas, Lithuania). Amplification with this primer pair 
results in 490 bp and 190 bp products corresponding to I and 
D alleles, respectively. PCR was carried out on the Robo 
Cycler 96 (Stratagene, USA) with initial denaturation at 94 
oC for 10 min, followed by 30 cycles at 94 
oC for 1 min, at 
58 
oC (annealing) for 1 min and at 72 
oC (extension) for 1 
min and then by a final extension period at 72
 oC for 10 min. 
PCR products were visualised on a 1.5 % agarose-gel con-
taining ethidium bromide. To reduce the incidence of 
mistyping ID as DD, each DD genotype was subjected to a 
second run of PCR with a primer pair 5’ TGG GAC CAC 
AGC GCC CGC CAC TAC 3’ and 5’ TCG CCA GCC CTC 
CCA TGC CCA TAA 3’ that recognizes the insertion-
specific sequence with the following program: 10 min de-
naturation at 94
oC, followed by 30 cycles at 94 
oC for 50 
seconds, at 62 
oC (annealing) for 50 seconds and at 72 
oC 
(extension) for 1 min. Under these conditions, only the I al-
lele produced a 335 bp amplicon. Genotyping was performed 
in a blinded fashion with respect to clinical status of patients 
and controls.  
Table 1.  ACE Polymorhisms in Patients with Idiopathic Parkinson’s Disease (PD) and Non-PD Controls 
  PD patients         non-PD controls  Total   
No. of subjects  77          50    127   
No. of chromosome  154          100    254   
Allele frequency               
  No.  %          No. % No.  % 
D  97   63.0          5 7     57.0 154  60.6 
I  57   37.0          4 3   43.0 100  39.4 
               P=0.6*    
  No.  % UPDRSm  UPDRS  total  H&Y ADL  Age  at  onset  No. % No.  % 
     Mean (SD)   Mean (SD)   Mean (SD)   Mean (SD)  Mean (SD)       
Genotype frequency                 
DD  30  39.0  34.4(21.3) 57.5(37.6)  2.8(1.1)  69.3%(22.7%)  61.8(12.7) 16  32.0 46  36.2 
DI  37  48.1  26.8(19.8) 44.7(31.8)  2.3(1.0)  77.3%(19.7%)  63.5(10.7) 25  50.0 62  48.8 
II  10  13.0  37.1(21.5) 60.3(39.4)  3.0(1.7)  55.0%(37.2%) 63.4(9.7)  9    18.0 19  15.0 
     P=0.16** P=0.23** P=0.09**  P=0.16**  P=0.98**  P=0.6*    
DD  30   39.0  34.4(21.3) 57.5(37.6)  2.8(1.1)  69.3%(22.7%)  61.8(12.7) 16    32.0 46  36.2 
DI&II  47   61.0  29.0(20.4)  48.0(33.7)  2.4(1.2)  72.5%(25.7%)  63.5(10.4)   34   68.0 81  63.8 
      P=0.16*** P=0.46*** P=0.09***  P=0.31***  P=0.92***    P=0.5*     
UPDRSm: motor part of the UPDRS scale; H&Y: Hoehn and Yahr scale; ADL: Activities of daily living scale; SD: standard deviation. 
* p value for the comparison of allele frequencies between PD patients and controls. 
** p value for the comparison UPDRSm, UPDRS total, H&Y, ADL and age at onset between PD patients of different genotype groups (DD, DI, II). 
*** p value for the comparison UPDRSm, UPDRS total, H&Y, ADL and age at onset between PD patients of different genotype groups (DD vs DI and II). 
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2.3. Statistical Analysis 
  Statistical analysis was performed using the SPSS for 
Windows release 11.0, run on an IBM-compatible computer. 
Mann-Whitney U test for two samples was used in non-
parametric comparisons of continuous data. Chi-square with 
Yates’s corrected p-value and 2-tailed Fischer’s exact test 
were used, as appropriate, for the comparison of proportions. 
For corrections of associations, multivariate analysis was 
performed using stepwise logistic regression. Adjustments 
were made for gender, age at onset and disease stage. The 
level of statistical significance was set at p<0.05. The study 
was approved by the local Institutional Review Board (IRB). 
3. RESULTS 
  Our study population consisted of 77 PD patients (43 
men and 34 women), age 35 to 89 years with the mean of 
69.2 (SD 10.4) years, and 50 control subjects (35 men and 
15) women, age 19 to 80 years with the mean of 49.5 (SD 
21.6) years. PD patients had a mean age of onset of 62.84 
(SD11.30) years (the age at onset of PD was defined as the 
appearance of the first symptom estimated by medical inter-
view). The mean duration of symptoms was 6.27 (SD 5.28) 
years. 
  The ACE I/D polymorphism genotypes and allele fre-
quencies are presented in Table 1. The distribution of II, ID 
and DD genotypes was not significantly different between 
PD patients and control subjects (p=0.6). The most frequent 
genotype was ID. There were fewer II genotypes 10 (13.0%) 
and more DD genotypes 30 (39.0%) in the PD patients. ACE 
genotypes for our cohort, PD cases and controls independ-
ently, were in Hardy–Weinberg equilibrium. The D and I 
allele distributions in the PD and control groups also re-
vealed no significant differences (p=0.6). The D alleles were 
more common in both groups (63.0% in the PD group and 
57.0% in the control group). No significant associations 
were observed when adjustment using stepwise logistic re-
gression was applied (p<0.05). 
  The most predominant symptoms at onset were bradyki-
nesia or rigidity related. At the time of examination, the 
mean total UPDRS was 51.7 (SD 35.4). The UPDRS sub-
scores were: UPDRSI 6.27 (SD 3.53), UPDRSII 15.82 (SD 
11.16), UPDRSII (or UPDRSm) 31.09 (SD 20.79), 
UPDRSIV 2.52 (SD 3.95). The mean Hoehn & Yahr score 
was 2.56 (SD 1.14) and mean Swab & England score was 
71.30% (SD24.46%). The main symptoms of PD at onset 
and examination, and the L-dopa induced motor side effects 
(dyskinesias, wearing-off and on-off phenomena), the vascu-
lar comorbid conditions (ischemic heart disease and cere-
brovascular disease) and family history of PD patients are 
presented in Table 2. The subgroup analysis of main PD 
symptoms and L-dopa motor side effects according to the 
presence or absence of the DD genotype (Table 2) revealed 
higher frequency of the DD phenotype in patients with the 
akinetic-rigid form of the disease and L-dopa induced motor 
complications. These differences were not statistically sig-
nificant. When results were analyzed by groups defined by 
phenotype and not by genotype, a marginally non-significant 
result was revealed: there were only 9 DD homozygotes 
(26.5%) in the patients with an initial tremor-dominant form 
of PD (n=34) compared to 21 DD homozygotes (48.8%) in 
the bradykinesia-rigidity dominant form (n=43) (Fisher exact 
test p=0.061 and Pearson 
2 test p=0.061). 
  Finally, we compared the distribution of the genotypes 
(DD, ID, II) in PD patients and control subjects categorized 
by age group. For PD patients we used the age of onset (age 
< 50, 50–59, 60–69 and 70 years). No statistically signifi-
cant differences were noted in the age subgroup analysis 
although patients with younger onset PD tended to have the 
DD phenotype more frequently. The results of this analysis 
are presented in Table 3. 
DISCUSSION 
  The ACE gene is located on chromosome 17q23 and 
consists of 26 exons and 25 introns. While ACE is best 
known for the conversion of angiotensin I to angiotensin II 
and for the degradation of bradykinin, this dipeptidyl car-
boxypeptidase has additional substrates. A substrate of spe-
cial interest with regard to PD is substance P [15], an unde-
capeptide that displays neuroprotective effects [16-18]. Sub-
stance P also increases rat locomotor activity when microin-
jected into discrete regions of the basal ganglia including the 
substantia nigra reticulata (SNr), substantia nigra compacta 
(SNc), ventral tegmental area (VTA), and globus pallidum 
Table 2.  Subgroup Analys is of Main PD Symptoms and L-Dopa Motor Side Effects According to ACE Genotypes 
  N (n=77, % of total )*  DD(%)** DI(%)**  II(%)**  p-value 
Initial  Symptoms       
Tremor dominant  34(44.2%)  9 (30.0%)  20(54.1%)  5(50.0%) 
B-R dominant   43(55.8%)  21 (70.0%)  17(45.9%)  5(50.0%) 
0.13 
Tremor  at  examination  52(67.5%) 18  (60.0%) 28(75.7%)  6(60.0%)  0.34 
Rigidity at examination  58(75.3%)  23 (76.7%)  27(73.0%)  8(80.0%)  0.88 
Instability at examination  38(49.4%)  18 (60.0%)  14(37.8%)  6(60.0%)  0.15 
Dyskinesias 15(19.5%)  7  (23.3%)  5(13.5%)  3(30.0%)  0.40 
On-off phenomena  22(28.6%)  13 (43.3%)  6(16.2%)  3(30.0%)  0.06 
B-R: bradykinesia rigidity; DI: deletion/insertion polymorphism; PD: Parkinson’s disease. 
*Percentage (%) of all PD patients. 
**Percentage of PD patients with each genotype. ACE Insertion/Deletion Polymorphism and Parkinson’s Disease  The Open Neurology Journal, 2008, Volume 2    69 
(GP) [19-22]. Several studies in rats have also shown that the 
substance P can increase dopamine outflow [23-27] as well 
as acetylcholine release [28] under normal conditions. 
  A deletion/insertion (D/I) polymorphism of ACE has 
been reported that arises from the presence or absence of a 
287-base pair sequence of intron 16 resulting in three geno-
types (DD/II homozygotes and ID heterozygote) [29]. Al-
though ACE activity is found in plasma, the majority of the 
biologically active enzyme is tissue-bound [30]. Tiret et al. 
[31] provided evidence that the insertion/deletion (ID) poly-
morphism is associated with higher plasma ACE activity. 
Later reports established that the DD genotype is also asso-
ciated with a higher tissue ACE activity [32]. As reduced 
neuroprotection is implicated in the pathogenesis of PD [33], 
one could speculate that the increased ACE activity in sub-
jects with a DD genotype could lower the levels of substance 
P, making them more susceptible to PD. Lower levels of 
substance P may also affect locomotion and dopamine 
modulatory mechanisms further contributing to the devel-
opment of PD. Interestingly, substance P levels and immuno-
reactivity are decreased in nigral and striatal tissues of ani-
mals models of PD and in postmortem samples of PD pa-
tients [16].  
  To test the hypothesis that the ACE I/D polymorphism is 
associated with PD, possibly through altering substance P 
levels, we determined ACE genotypes in PD patients and 
compared them to non-PD controls. The frequency of the 
DD genotype and the D allele was higher in the PD popula-
tion. The frequency of the DD phenotype was also higher in 
younger patients and in patients with the akinetic-rigid type 
of PD. However, statistical significance was not reached in 
any of the comparisons made throughout our study. How-
ever, the marginally non-significant increased prevalence of 
DD homozygotes in the akinetic-rigid predominant PD pa-
tients may suggest that the I/D polymorphism has disease 
modifying effects. Mellick et al. [6] were the first to investi-
gate the possible involvement of the ACE gene in the patho-
genesis of PD in a population of Caucasians. Based on evi-
dence linking the DD ACE genotype to longevity [34] they 
suggested that D allele may confer some long-term protec-
tive effect as a result of ACE' s action on neuropeptides and 
neuroendocrine function. In their study similar frequencies 
were reported for the D and I alleles in the PD (D 48% and I 
52%) and control population (D 54% and I 46%). Further-
more, the genotype distribution was also similar in the PD 
and control group (the most frequent phenotype was ID in 
52% of PD patients and 56% of controls). Our results are in 
agreement with those of Mellick et al. that also failed to pro-
vide evidence that the ACE polymorphism is related to PD. 
Both our studies report similar allele frequencies in the con-
trol groups confirming previous results (the reported D allele 
frequency in Caucasians is 50–58% [35, 36]. 
  In a different study, Lin et al. [5] also evaluated the pos-
sible relationship between the ACE polymorphism and PD in 
a Chinese population. The frequency of the homozygote DD 
genotype of the ACE gene was increased in the PD group 
(22% in the PD vs 12% in the control group), but the statisti-
cal significance was marginal (p = 0.048). The increase in 
the DD genotype in the PD group was also noted in our 
study (39% in the PD vs 32% in the control group) but sig-
nificance was not reached. One could speculate that various 
reasons like ethnicity, (Caucasians and Chinese have differ-
ent genetic backrounds), sample size and different recruit-
ment methods used for the control population could account 
for this difference in significance between the two studies. In 
normal Chinese the D allele frequency is 35–39% [36]. The 
frequency of D allele in the control subjects in the study by 
Lin et al. (33%) was markedly different from that in our re-
port (57%) and Mellick’s study (54%). However, this is in 
accordance with the frequencies of the D allele in Caucasian 
and Chinese populations.  
  Our study has certain strengths and limitations. We ac-
knowledge the relatively small sample size and highlight the 
preliminary nature of these findings. Strengths of our study 
include its prospective nature and the homogeneity of the 
sample population. 
  Based on the evidence presented herein, we conclude that 
the ACE insertion/deletion polymorphism is not associated 
with PD and that ACE genotypes do not correlate signifi-
cantly with any of the symptoms of the disease in Cauca-
sians, although a disease modifying effect cannot be ex-
cluded. Our data suggest that ACE genotype is unlikely to be 
an important determinant of susceptibility to PD.  
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Table 3.  Comparison ACE Genotypes in PD Patients and Control Subjects Categorized by Age Group 
  PD group  
(N = 77) 
    Control subjects  
(N = 50) 
   p-value 
 N  DD  DI    II  N  DD  DI  II   
Total  77  30 (39.0%)  37 (48.0%)  10 (13.0%)  50  16 (32.0%)  25 (50.0%)  9 (18.0%)  0.63 
< 50  12  7(58.3%)  4 (33.3%)  1 (8.3%)  25  9 (36.0%)  11 (44.0%)  5 (20.0%)  0.40 
50–59  11  1 (9.1%)  7 (63.3%)  3 (27.3%)  3  0 (0.0%)  1 (33.3%)  2 (66.7%)  0.43 
60–69  30  12 (40.0%)  15 (50.0%)  3 (10.0%)  10  2 (20.0%)  7 (70.0%)  1 (10.0%)  0.50 
70  24  10 (41.7%)  11 (45.8%)  3 (12.5%)  12  5 (41.7%)  6 (50.0%)  1 (8.3%)  0.93 
D/I: deletion/insertion polymorphism; PD: Parkinson’s disease. 70    The Open Neurology Journal, 2008, Volume 2  Papapetropoulos et al. 
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